Table 1.
Baseline and post-treatment characteristics of the patients
| Patient | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| Age at diagnosis (years) | 56 | 68 | 76 | 70 | 73 | 47 |
| Sex | Female | Female | Male | Male | Female | Male |
| NYHA class at diagnosis | IV | III–IV | III | IV | III | II |
| NYHA class 8 weeks after treatment | II | I–II | II | III | II | II |
| LVEF at diagnosis (%) | 29 | 45 | 19 | 14 | 24 | 22 |
| LVEF 4 weeks after treatment (%) | 46 | 53 | 31 | 23 | 37 | 25 |
| LVEDD at diagnosis (mm) | 57 | 55 | 70 | 76 | 72 | 74 |
| LVEDD after treatment (mm) | 47 | 44 | 64 | 65 | 60 | 72 |
| CD20+ count in diagnostic biopsy (cells/mm2) | 20.25 | 633 | 11 | >7 | >7 | 10 |
| CD20+ count in follow-up biopsy (cells/mm2) | ND | ND | 6.52 | ND | ND | 17.5 |
| CD3+ count in diagnostic biopsy (cells/mm2) | 7.4 | 638 | 8.5 | 10.2 | 3.1 | 23 |
| CD3+ count in follow-up biopsy (cells/mm2) | 2.8 | 6.3 | 6.2 | 6 | 6.8 | 82 |
| Mac-1 count in diagnostic biopsy (cells/mm2) | 43 | 230 | 38.4 | 60.7 | 30.8 | 48.57 |
| Mac-1 count in follow-up biopsy (cells/mm2) | 16.3 | 30 | 43.3 | 21.1 | 52 | 120 |
| NT-proBNP at diagnosis (pg/mL) | 2544 | 3316 | 15 318 | 1555 | 7800 | 1329 |
| NT-proBNP after treatment (pg/mL) | 1293 | 362 | 11 814 | 2197 | 4230 | 789 |
LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; ND, not detectable (below technical detection limit); NT-proBNP, N-terminal pro-B-type natriuretic peptide.